Valentina X. Cannone

Parma, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Sex-based differences in metabolic protection by the ANP genetic variant rs5068 in the general population.

Sex-based differences in metabolic protection by the ANP genetic variant rs5068 in the general population.

Journal: American journal of physiology. Heart and circulatory physiology

Published: July 07, 2023

MANP in Hypertension With Metabolic Syndrome: Proof-of-Concept Study of Natriuretic Peptide-Based Therapy for Cardiometabolic Disease.

MANP in Hypertension With Metabolic Syndrome: Proof-of-Concept Study of Natriuretic Peptide-Based Therapy for Cardiometabolic Disease.

Journal: JACC. Basic to translational science

Published: May 15, 2023

Evidence for Angiotensin II as a Naturally Existing Suppressor for the Guanylyl Cyclase A Receptor and Cyclic GMP Generation.

Evidence for Angiotensin II as a Naturally Existing Suppressor for the Guanylyl Cyclase A Receptor and Cyclic GMP Generation.

Journal: International journal of molecular sciences

Published: April 10, 2023

EVIDENCE FOR ANGIOTENSIN II AS A NATURALLY EXISTING SUPPRESSOR FOR THE NATRIURETIC PEPTIDE SYSTEM.

EVIDENCE FOR ANGIOTENSIN II AS A NATURALLY EXISTING SUPPRESSOR FOR THE NATRIURETIC PEPTIDE SYSTEM.

Journal: bioRxiv : the preprint server for biology

Published: February 07, 2023

Natriuretic peptide pathways in heart failure: further therapeutic possibilities.

Natriuretic peptide pathways in heart failure: further therapeutic possibilities.

Journal: Cardiovascular research

Published: May 16, 2022

Evidence for a Prehypertensive Water Dysregulation Affecting the Development of Hypertension: Results of Very Early Treatment of Vasopressin V1 and V2 Antagonism in Spontaneously Hypertensive Rats.

Evidence for a Prehypertensive Water Dysregulation Affecting the Development of Hypertension: Results of Very Early Treatment of Vasopressin V1 and V2 Antagonism in Spontaneously Hypertensive Rats.

Journal: Frontiers in cardiovascular medicine

Published: March 15, 2022

Natriuretic Peptides and Blood Pressure Homeostasis: Implications for MANP, a Novel Guanylyl Cyclase a Receptor Activator for Hypertension.

Natriuretic Peptides and Blood Pressure Homeostasis: Implications for MANP, a Novel Guanylyl Cyclase a Receptor Activator for Hypertension.

Journal: Frontiers in physiology

Published: November 15, 2021

First-in-Human Study of MANP: A Novel ANP (Atrial Natriuretic Peptide) Analog in Human Hypertension.

First-in-Human Study of MANP: A Novel ANP (Atrial Natriuretic Peptide) Analog in Human Hypertension.

Journal: Hypertension (Dallas, Tex. : 1979)

Published: October 18, 2021

STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure.

STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure.

Journal: JACC. Basic to translational science

Published: March 19, 2021

Electrolyte Disorders Induced by Antineoplastic Drugs.

Electrolyte Disorders Induced by Antineoplastic Drugs.

Journal: Frontiers in oncology

Published: December 28, 2019

Posterior reversible encephalopathy syndrome in an oncological normotensive patient: evidence for a pathogenic role of concomitant low magnesium serum levels and chemotherapy treatment.

Posterior reversible encephalopathy syndrome in an oncological normotensive patient: evidence for a pathogenic role of concomitant low magnesium serum levels and chemotherapy treatment.

Journal: Acta bio-medica : Atenei Parmensis

Published: July 18, 2019

Atrial Natriuretic Peptide: A Molecular Target of Novel Therapeutic Approaches to Cardio-Metabolic Disease.

Atrial Natriuretic Peptide: A Molecular Target of Novel Therapeutic Approaches to Cardio-Metabolic Disease.

Journal: International journal of molecular sciences

Published: June 16, 2019

Showing 1-12 of 27

Last Updated: 09/26/2026